Thus, combining alectinib, a TKI that leads to antigen release, with atezolizumab, an immune checkpoint inhibitor (ICI) that releases T-cell inhibition to drive tumor cell death, has the potential to produce additive and durable antitumor effects in patients with ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.